Vi­iV Health­care looks to make long-act­ing HIV pre­ven­tion shot ac­ces­si­ble in low- and mid­dle-in­come coun­tries

The Joint Unit­ed Na­tions Pro­gramme on HIV and AIDS set a lofty goal back in 2019 to end the HIV epi­dem­ic by 2030. But ac­cord­ing to the World Health Or­ga­ni­za­tion, in­fec­tion rates are not falling rapid­ly enough to meet that tar­get.

GSK’s Vi­iV Health­care thinks it can help change that.

On Fri­day, Vi­iV an­nounced that it’s in talks with the UN-backed Med­i­cines Patent Pool (MPP) for patent rights to its cabote­gravir long-act­ing HIV in­jectable for pre-ex­po­sure pro­phy­lax­is (PrEP) in low- and mid­dle-in­come coun­tries.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER